Ivax has received approval from the Medicine and Healthcare Products Regulatory Agency for Fluticasone nasal spray in 11 countries across Europe. Fluticasone is the generic equivalent of Flixonase (known in the U.S. as Flonase), marketed by GlaxoSmithKline for the treatment of rhinitis.
There are no other known generic alternatives presently marketed in Europe. Fluticasone nasal spray has already been approved in the UK and was launched in May. Ivax also has an abbreviated new drug application for Fluticasone pending with the FDA.